01—Abstract
Summary
Summary of the 8-K filed January 9, 2024. Cited figures are marked; the original filing is the authoritative source.
Cardinal Health (CAH) issued an 8-K on January 9, 2024 announcing progress on its ongoing business and portfolio review, an updated enterprise operating and segment reporting structure effective January 1, 2024, and a raised fiscal 2024 non-GAAP diluted EPS outlook.
The company completed its review of the growth businesses within the Medical Segment, deciding to invest in and further develop at-Home Solutions (a $2.6Ba revenue home medical supplies provider) and OptiFreight Logistics (a $250M revenue healthcare logistics business), while the review of Global Medical Products and Distribution (GMPD) continues under the Medical Improvement Plan. The reporting structure is being reorganized into two reportable segments, Pharmaceutical and Specialty Solutions and GMPD, with at-Home Solutions, OptiFreight Logistics, and Nuclear and Precision Health Solutions moved into a new "Other" category. Reporting under the new structure begins with fiscal Q3 2024, and fiscal Q2 2024 results will still be reported on the former segment basis on February 1, 2024.
Management also reiterated long-term non-GAAP diluted EPS growth of 12% to 14% and provided pro-forma long-term segment targets. The fiscal 2024 non-GAAP diluted EPS guidance was moved to the high end of its $6.75 to $7.00b range, driven mainly by favorability in Interest and Other expense and diluted share count, supported by strong cash flow and a new $250M accelerated share repurchase. The company also said fiscal Q2 2024 Medical segment profit will be roughly flat with Q1 due to anticipated non-recurring adjustments, though it stated these do not affect progress toward its fiscal 2026 targets, including at least $650M of Medical Improvement Plan segment profit.
02—Key points
Key Highlights
- Fiscal 2024 non-GAAP diluted EPS guidance raised to the high end of the $6.75 to $7.00 range, driven by lower interest/other expense and fewer diluted shares rather than operating changes.
- Completed review of Medical Segment growth businesses: Cardinal will invest in at-Home Solutions ($2.6B revenue) and OptiFreight Logistics ($250M revenue), including a new Texas distribution center.
- GMPD business review continues, with focus on the Medical Improvement Plan targeting at least $650M of segment profit by fiscal 2026 and ~$300M GMPD segment profit by FY26.
- New reporting structure effective January 1, 2024: Pharmaceutical and Specialty Solutions and GMPD become reportable segments, while at-Home Solutions, OptiFreight, and Nuclear and Precision Health Solutions move to "Other"; the change is reflected in reporting from fiscal Q3 2024.
- Fiscal Q2 2024 Medical segment profit now expected to be generally consistent with Q1 due to anticipated non-recurring adjustments, a negative near-term signal for the former Medical segment.
- Reiterated long-term non-GAAP diluted EPS growth target of 12% to 14% and provided pro-forma segment targets (Pharma 4-6% segment profit CAGR; Other 8-10% CAGR).
- New $250M accelerated share repurchase program executed in fiscal Q2 2024 supports EPS through a lower share count.
03—Questions
Frequently Asked Questions
Why did Cardinal Health raise its fiscal 2024 EPS guidance?
The company moved its non-GAAP diluted EPS guidance to the high end of its $6.75 to $7.00 range. The increase reflects anticipated favorability in Interest and Other expense and diluted weighted average shares outstanding, driven by strong cash flow generation, higher-than-expected cash balances, and a new $250M accelerated share repurchase in fiscal Q2 2024. The update does not indicate a change in operating performance.
What is changing in Cardinal Health's segment reporting?
Effective January 1, 2024, the company operates under two reportable segments: Pharmaceutical and Specialty Solutions (formerly Pharmaceutical, excluding Nuclear and Precision Health Solutions) and Global Medical Products and Distribution (GMPD, formerly Medical, excluding at-Home Solutions and OptiFreight). A new "Other" category includes at-Home Solutions, OptiFreight Logistics, and Nuclear and Precision Health Solutions. The new structure will be reflected in financial reporting beginning with fiscal Q3 2024, and fiscal Q2 2024 results will still follow the former segments.
Why is Medical segment profit expected to be flat in fiscal Q2 2024?
Management said utilization trends, Cardinal Health brand volumes, and inflation mitigation in GMPD are tracking to expectations. However, it now expects fiscal Q2 2024 Medical segment profit to be generally consistent with Q1 because of anticipated non-recurring adjustments in the quarter. The company states these adjustments do not change its progress toward previously communicated fiscal 2026 targets.
Is Cardinal Health selling or keeping its Medical businesses?
The company is keeping and investing in its growth businesses in the Medical Segment, at-Home Solutions and OptiFreight Logistics, which it views as drivers of long-term shareholder value. Its review of the Global Medical Products and Distribution business is still ongoing and focuses on executing the Medical Improvement Plan. The filing does not announce any divestiture, so investors should watch for updates on the GMPD review.
What are Cardinal Health's long-term financial targets?
The company reiterated a long-term non-GAAP diluted EPS growth target of 12% to 14%. It also provided pro-forma targets under the new structure: Pharmaceutical and Specialty Solutions segment profit CAGR of 4-6%, GMPD segment profit of about $300 million by FY26 (from a preliminary FY23 base of about $(165) million), and Other segment profit CAGR of 8-10%. These FY23 recast figures are preliminary and will be finalized by the Q3 FY24 earnings release.
04—Continue